Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Nitrite decreases sickle hemoglobin polymerization in vitro independently of methemoglobin formation

Toxicology and Applied Pharmacology(2023)10.1016/j.taap.2023.116606Source: DataRank Database

Nitrite decreases sickle hemoglobin polymerization in vitro independently of methemoglobin formation is a research paper published in Toxicology and Applied Pharmacology (2023). On theSindex it has a DataRank of 0. It has been cited 3 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access3 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Topics (29)IDs (PubMed, PMC)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Meghann L. Smith ORCID,Sayuri Kamimura ORCID,Sebastian Vogel ORCID,Celia M. de Souza Batista,Zenaide Quezado ORCID

Live enrichment

PubMed:37336294 PMC:PMC10387360

National Institutes of Health

Grant: 1ZIACL090052-05

Neurobiology of pain and behavior changes associated with rare diseases and developmental disabilities

National Institutes of Health

Grant: 1ZIACL090053-05

Pathobiology of pain in sickle cell disease

National Institutes of Health

Grant: 1ZIACL090054-05

Development of novel strategies for the treatment of pain in children

Intramural NIH HHS

Grant: ZIA CL090053

Intramural NIH HHS

Grant: ZIA CL090052

Intramural NIH HHS

Grant: ZIA CL090054

NIH Clinical Center

Fields of Study

0301 basic medicine03 medical and health sciencesAnimalsMiceHemoglobin, SickleMethemoglobinNitritesLeukocytosisAnemia, Sickle Cell

MeSH Terms

AnimalsMiceAnemia, Sickle CellLeukocytosisNitritesHemoglobin, SickleMethemoglobin

Keywords

NitritePolymerizationNitrateheminMethemoglobinSickleDimethyl AdipimidateMiceLeukocytosisHemoglobin, SickleAnimalsAnemia, Sickle CellNitrites

Related Papers (10)

Sickle cell disease mice have cerebral oxidative stress and vascular and white matter abnormalities

N/A

0.360DataRank · unranked

Blood Cells Molecules and Diseases(2020)

co-cited

10.1016/j.bcmd.2020.102493

Locomotor mal-performance and gait adaptability deficits in sickle cell mice are associated with vascular and white matter abnormalities and oxidative stress in cerebellum

Brain Research(2020)

co-cited

10.1016/j.brainres.2020.146968

Mitochondrial localization and moderated activity are key to murine erythroid enucleation

Blood Advances(2021)

co-cited

10.1182/bloodadvances.2021004259

A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease

N/A

2.4DataRank · unranked

Blood(2022)

co-cited

10.1182/blood.2022015403

Mitapivat increases ATP and decreases oxidative stress and erythrocyte mitochondria retention in a SCD mouse model

Blood Cells Molecules and Diseases(2022)

co-cited

10.1016/j.bcmd.2022.102660

Genetic variants of PKLR are associated with acute pain in sickle cell disease

Blood Advances(2022)

co-cited

10.1182/bloodadvances.2021006668

Mouse models of sickle cell disease: Imperfect and yet very informative

Blood Cells Molecules and Diseases(2023)

co-cited

10.1016/j.bcmd.2023.102776

Reticulocyte mitochondrial retention increases reactive oxygen species and oxygen consumption in mouse models of sickle cell disease and phlebotomy-induced anemia

Experimental Hematology(2023)

co-cited

10.1016/j.exphem.2023.02.005

Birth Prevalence of Sickle Cell Disease and County-Level Social Vulnerability — Sickle Cell Data Collection Program, 11 States, 2016–2020

Top 22%

0.938DataRank

MMWR Morbidity and Mortality Weekly Report(2024)

co-cited

10.15585/mmwr.mm7312a1

Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease

N/A

0.766DataRank · unranked

Blood Advances(2024)

co-cited

10.1182/bloodadvances.2023012467